Effectiveness of carrot seeds in female with decreased libido

Evaluation of the effectiveness of carrot seeds in women with Hypoactive sexual desire disorder(HSDD) during reproductive age : double- bind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180224038847N1

Enrollment

Registered

2018-05-01

Start date

2018-05-22

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lack or loss of sexual desire. Hypoactive sexual desire disorder

Interventions

Intervention 1: Intervention group: Capsule contains 500mg carrot seeds three times daily. Intervention 2: Control group: Capsule contains 500mg of the placebo three times daily.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Loss or decrease in sexual desire according to DSM-4 criteria 18-45 years old Having a spouse who spends at least half a month with his family Normal pelvic exam Normal Pap smear At least 6 month duration of marriage

Exclusion criteria

Exclusion criteria: Serious medical or chronic disease Sever depression, suicidal, psychotic disease Menopause Divorce intent Pregnancy Lactation Skin allergy to Umbelliferac Familial problem

Design outcomes

Primary

Measure	Time frame
Libido. Timepoint: At beginning of the trial, 6 weeks and 12weeks after starting drug or placebo. Method of measurement: FSFI questionaire.	—

Secondary

Measure	Time frame
Arousal. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Dysparonia. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Satisfaction. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Orgasm. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Lubrication. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Total sexual function. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Frequency of probable adverse effect of the drug. Timepoint: Weekly after starting the drug. Method of measurement: Phone report by patient.;Depression. Timepoint: At beginning and after finishing of the intervention. Method of measurement: Beck Deppression Inventory test(BDI).	—

Measure

Time frame

Arousal. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Dysparonia. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Satisfaction. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Orgasm. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Lubrication. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Total sexual function. Timepoint: At beginning of the trial, 6 weeks and 12 weeks after starting drug or placebo. Method of measurement: FSFI questonnaire.;Frequency of probable adverse effect of the drug. Timepoint: Weekly after starting the drug. Method of measurement: Phone report by patient.;Depression. Timepoint: At beginning and after finishing of the intervention. Method of measurement: Beck Deppression Inventory test(BDI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRosita Bahrami

Iran University of Medical Sciences

rositabahrami@yahoo.com+98 21 5515 2191

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026